Supplementary Online Content

Tachihara M, Tsujino K, Ishihara T, et al. Durvalumab plus concurrent radiotherapy for treatment of locally advanced non–small cell lung cancer: the DOLPHIN phase 2 nonrandomized controlled trial. Published online September 7, 2023. *JAMA Onocol*. doi:10.1001/jamaoncol.2023.3309

eTable 1. Inclusion and Key Exclusion Criteria
eTable 2. Antitumor Efficacy
eTable 3. Adverse Events of Any Cause in ≥10% of Patients
eFigure 1. Study Schema
eFigure 2. Progression-Free Survival Subgroup Analyses by Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Inclusion and Key Exclusion Criteria

Inclusion criteria
<The primary inclusion criteria>
Age ≥20 years old
ECOG performance status of 0 or 1
Histologic evidence of NSCLC
Suspected locally advanced NSCLC (stage IIIA, B, C) or postoperative recurrence
With measurable lesions
Availability of tumor tissue for IHC
Adequate organ and bone marrow function
SpO_2 ≥93%
No history of thoracic radiation therapy and chemotherapy
24 weeks have passed since adjuvant chemotherapy
Life expectancy of ≥12 weeks
Body weight ≥30kg
Written informed consent
<The secondary inclusion criteria>
Confirmed unresectable locally advanced NSCLC is curable by the radiation protocol
Irradiation is possible (60 Gy in 30 fractions prescribed to D95% of PTV to involved fields)
PD-L1 positive of tumor cells (SP263)
Key Exclusion criteria
Active double cancer
Active infection, including tuberculosis, hepatitis B and C
Interstitial lung disease detected by chest-CT
Complication of active autoimmune disease
Prescription of more than 10mg PSL continuously

Abbreviations: NSCLC, non–small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; IHC, Immunohistochemistry; SpO_2, arterial oxygen saturation of pulse oximetry; PD-L1, programmed cell death ligand-1; CT, computed tomography; PSL, prednisolone.

eTable 2. Anti-Tumor Efficacy

Anti-tumor efficacy	n=33
Confirmed ORR, No. %(95% CI)	30, 90.9% (75.7-98.1)
DCR, No. (%, 95% CI)	33, 100% (89.4-100.0)
Best overall response by ICR, No. (%)	
CR	11 (33.3)
PR	19 (57.6)
SD	3 (9.1)
PD	0 (0.0)
Median DOR, months (95% CI)	NR (14.9-NE)

Abbreviations: ORR, overall response rate; ICR, independent central review; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; DOR, duration of response.

eTable 3. Adverse Events of Any Cause in ≥10% of Patients

Event	Any grade	Grade 3 or 4	Grade 5
	No. (%)		
Any events	34 (100)	18 (52.9)	2 (5.9)
Radiation dermatitis	15 (44.1)	0	0
Pneumonitis	14 (41.2)	4 (11.8)	0
Constipation	11 (32.4)	0	0
Radiation pneumonitis	9 (26.5)	0	0
Esophagitis	9 (26.5)	0	0
Lung infection	8 (23.5)	3 (8.8)	1 (2.9)
Dermatitis	8 (23.5)	0	0
Diarrhea	7 (20.6)	0	0
Hypothyroidism	7 (20.6)	0	0
Hyperthyroidism	6 (17.6)	0	0
Pyrexia	6 (17.6)	0	0
Pruritus	6 (17.6)	0	0
Rash	8 (17.6)	0	0
Anemia	6 (17.6)	0	0
Thrombocytopenia	6 (17.6)	1 (2.9)	0
Cough	5 (14.7)	0	0
Fatigue	5 (14.7)	0	0
Amylase increased	5 (14.7)	1 (2.9)	0
Lipase increased	5 (14.7)	1 (2.9)	0
Lymphocyte count decreased	5 (14.7)	5 (14.7)	0
Nausea	4 (11.8)	0	0
Decreased appetite	4 (11.8)	0	0
Musculoskeletal pain	4 (11.8)	0	0
Hyperglycemia	4 (11.8)	3 (8.8)	0
AST increased	4 (11.8)	2 (5.9)	0
Leukopenia	4 (11.8)	0	0

eFigure 1. Study Schema



Primary endpoint: 12-month PFS rate from 2nd registration (assessed by independent central review)

Secondary endpoints: PFS, OS, objective response rate, disease control rate, time to death or distant metastasis, treatment completion rate, and safety

eFigure 2. Progression-Free Survival Subgroup Analyses by Characteristics

		n	Hazard ratio[95%CI]
Sex	Male	29	1.755 [0.230, 13.369]
	Female	4	Reference
Age	<75y	19	Reference
	≥75y	14	2.682 [0.952, 7.553]
Pathology	Squamous	14	1.383 [0.485, 3.949]
	Adenocarcinoma	18	Reference
Onset	Primary	24	Reference
	Recurrence	9	0.156 [0.020, 1.188]
Stage	ⅢA	15	Reference
	ⅢB/C	10	1.094 [0.378, 3.168]
ORR	SD	3	10.366 [2.421, 44.385]
	CR+PR	30	Reference
PD-L1	1-24%	13	Reference
	≥25%	20	0.962 [0.341, 2.710]
PD-L1	1-49%	15	Reference
	≥50%	18	0.671 [0.243, 1.856]
ECOG PS	0	17	Reference
	1	16	1.591 [0.574, 4.412]